Sfoglia per Autore
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803
2011-01-01 Sargent, D; Shi, Q; Yothers, G; Van Cutsem, E; Cassidy, J; Saltz, L; Wolmark, N; Bot, B; Grothey, A; Buyse, M; de Gramont, A; Green, E; Grothey, A; Alberts, Sr; Bot, B; Campbell, M; Shi, Q; O'Connell, Mj; Wolmark, N; de Gramont, A; Gray, R; Kerr, D; Haller, Dg; Benedetti, J; Buyse, M; Labianca, R; Seitz, Jf; O'Callaghan, Cj; Francini, G.; Catalano, Pj; Blanke, Cd; Andre, T; Goldberg, Rm; Benson, A; Twelves, C; Cassidy, J; Sirzen, F; Cisar, L; Van Cutsem, E; Saltz, L; Adjuvant Colon Cancer End-points (ACCENT), Group
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
2011-01-01 Yothers, G; Sargent, Dj; Wolmark, N; Goldberg, Rm; O'Connell, Mj; Benedetti, Jk; Saltz, Lb; Dignam, Jj; Blackstock, Aw; Green, E; Grothey, A; Alberts, Sr; Bot, B; Campbell, M; Shi, Q; de Gramont, A; Gray, R; Kerr, D; Haller, Dg; Buyse, M; Labianca, R; Seitz, Jf; O'Callaghan, Cj; Francini, G; Catalano, Pj; Blanke, Cd; Andre, T; Goldberg, Rm; Sanoff, H; Benson, A; ACCENT Collaborative, Group
A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity
2011-01-01 Montagnani, F.; Chiriatti, A.; Turrisi, G.; Francini, G.; Fiorentini, G.
Doxetacel and epirubicin compared with doxetacel and prednisone in advanced castrate-resistant prostate cancer: a randomized phase II study
2011-01-01 Petrioli, R.; Pascucci, A.; Conca, R.; Chiriacò, G.; Francini, E.; Bargagli, G.; Fiaschi, A. I.; Manganelli, A.; De Rubertis, G.; Barbanti, G.; Ponchietti, R.; Francini, G.
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients
2011-01-01 Vincenzi, B.; Galluzzo, S.; Santini, D.; Rocci, L.; Loupakis, F.; Correale, P.; Addeo, R; Zoccoli, A.; Napolitano, A.; Graziano, F.; Ruzzo, A.; Falcone, A.; Francini, G.; Dicuonzo, G.; Tonini, G.
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy
2010-01-01 Correale, P.; Rotundo, M. S.; DEL VECCHIO, M. T.; Remondo, C.; Migali, C.; Ginanneschi, C.; Tsang, K. Y.; Licchetta, A.; Mannucci, S.; Loiacono, L.; Tassone, P.; Francini, G.; Tagliaferri, P.
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients
2010-01-01 Correale, P.; Remondo, C.; Carbone, S. F.; Ricci, V.; Migali, C.; Martellucci, I.; Licchetta, A.; Addeo, R.; Volterrani, L.; Gotti, G.; Rotundo, M. S.; Tassone, P.; Sperlongano, P.; Abbruzzese, A.; Caraglia, M.; Tagliaferri, P.; Francini, G.
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin
2010-01-01 Petrioli, R.; Bargagli, G.; Lazzi, Stefano; Pascucci, A.; Francini, E.; Bellan, Cristiana; Conca, R.; Martellucci, I.; Fiaschi, A. I.; Lorenzi, B.; Francini, Guido; Multidisciplinary Oncology Group in Gastrointestinal, Tumors; Civitelli, Serenella
Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate
2010-01-01 Licchetta, A; Correale, P; Migali, C; Remondo, C; Francini, E; Pascucci, A; Magliocca, A; Guarnieri, Alfredo; Savelli, Vinno; Piccolomini, Alessandro; Carli, ANTON FERDINANDO; Francini, Guido
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractionated cisplatimum, oral etoposide, and bevacizumab
2009-01-01 C., Remondo; C., Migali; I., Martellucci; F., Carbone; V., Ricci; R., Addeo; S., Del Prete; F., Fulfaro; Francini, Guido; P., Correale
Association of immune-regulatory (FoxP3+)-T-cell tumor infiltration status with benefit from chemoimmunotherapy with gemcitabine, oxaliplatin, 5-FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients
2009-01-01 Correale, P.; Tagliaferri, P.; Del Vecchio, M. T.; Remondo, C.; Migali, C.; Tsang, Ky.; Rotundo, M. S.; Fulfaro, F.; Tassone, P.; Francini, G.
Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine.
2009-01-01 Correale, P; Miano, S. T; Remondo, C; Migali, C; Rotundo, M. S; Macrì, P; Tagliaferri, P; Tassone, P; Caraglia, M; Gotti, G; Francini, G.
Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials.
2009-01-01 Sargent, D; Sobrero, A; Grothey, A; O'Connell, Mj; Buyse, M; Andre, T; Zheng, Y; Green, E; Labianca, R; O'Callaghan, C; Seitz, Jf; Francini, Guido; Haller, D; Yothers, G; Goldberg, R; DE GRAMONT, A.
Immune-regulatory (FoxP3+)-T-cell tumor infiltration status is predictive of benefit from chemo-immunotherapy with gemcitabine, oxaliplatin, 5FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients
2009-01-01 Remondo, C; Tagliaferri, P; Rotundo, M S; Tassone, P; Del Vecchio, M T; Migali, C; Francini, G; Correale, P
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractioned cisplatinum, oral etoposide and bevacizumab: phase IB/II study
2009-01-01 Correale, P.; Remondo, C.; Migali, C.; Licchetta, A.; Martellucci, I.; Carbone, S. F.; Ricci, V.; Addeo, R.; Del Prete, S.; Francini, Guido
Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.
2008-01-01 Correale, P; DEL VECCHIO, MARIA TERESA; LA PLACA, M; Montagnani, F; DI GENOVA, G; Savellini, Gg; Terrosi, C; Mannucci, S; Giorgi, G; Francini, G.; Cusi, Mg
Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.
2008-01-01 Petrioli, R; Pascucci, A; Francini, E; Marsili, S; Sciandivasci, A; Tassi, R; Civitelli, Serenella; Tanzini, G; Lorenzi, Marco; Francini, Guido
Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen
2008-01-01 Correale, P.; Fioravanti, A.; Bertoldi, I.; Montagnani, F.; Miracco, C.; Francini, G.
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors
2008-01-01 Petrioli, R.; Pascucci, A.; Francini, E.; Marsili, S.; Fiaschi, A. I.; Civitelli, S.; Tanzini, G.; Battistelli, S.; Lorenzi, M.; Roviello, F.; Francini, G.
Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine.
2008-01-01 Correale, P; DEL VECCHIO, MARIA TERESA; Renieri, Tommaso; DI GENOVA, Giuseppa; LA PLACA, M; Remondo, Cinzia; Savellini, Gg; Terrosi, C; Zurbriggen, R; Amacker, M; Francini, Guido; Cusi, MARIA GRAZIA
| Titolo | Data di pubblicazione | Autore(i) | File | Abstract |
|---|---|---|---|---|
| Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803 | 1-gen-2011 | Sargent, D; Shi, Q; Yothers, G; Van Cutsem, E; Cassidy, J; Saltz, L; Wolmark, N; Bot, B; Grothey, A; Buyse, M; de Gramont, A; Green, E; Grothey, A; Alberts, Sr; Bot, B; Campbell, M; Shi, Q; O'Connell, Mj; Wolmark, N; de Gramont, A; Gray, R; Kerr, D; Haller, Dg; Benedetti, J; Buyse, M; Labianca, R; Seitz, Jf; O'Callaghan, Cj; Francini, G.; Catalano, Pj; Blanke, Cd; Andre, T; Goldberg, Rm; Benson, A; Twelves, C; Cassidy, J; Sirzen, F; Cisar, L; Van Cutsem, E; Saltz, L; Adjuvant Colon Cancer End-points (ACCENT), Group | - | |
| Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. | 1-gen-2011 | Yothers, G; Sargent, Dj; Wolmark, N; Goldberg, Rm; O'Connell, Mj; Benedetti, Jk; Saltz, Lb; Dignam, Jj; Blackstock, Aw; Green, E; Grothey, A; Alberts, Sr; Bot, B; Campbell, M; Shi, Q; de Gramont, A; Gray, R; Kerr, D; Haller, Dg; Buyse, M; Labianca, R; Seitz, Jf; O'Callaghan, Cj; Francini, G; Catalano, Pj; Blanke, Cd; Andre, T; Goldberg, Rm; Sanoff, H; Benson, A; ACCENT Collaborative, Group | - | |
| A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity | 1-gen-2011 | Montagnani, F.; Chiriatti, A.; Turrisi, G.; Francini, G.; Fiorentini, G. | - | |
| Doxetacel and epirubicin compared with doxetacel and prednisone in advanced castrate-resistant prostate cancer: a randomized phase II study | 1-gen-2011 | Petrioli, R.; Pascucci, A.; Conca, R.; Chiriacò, G.; Francini, E.; Bargagli, G.; Fiaschi, A. I.; Manganelli, A.; De Rubertis, G.; Barbanti, G.; Ponchietti, R.; Francini, G. | - | |
| Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients | 1-gen-2011 | Vincenzi, B.; Galluzzo, S.; Santini, D.; Rocci, L.; Loupakis, F.; Correale, P.; Addeo, R; Zoccoli, A.; Napolitano, A.; Graziano, F.; Ruzzo, A.; Falcone, A.; Francini, G.; Dicuonzo, G.; Tonini, G. | - | |
| Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy | 1-gen-2010 | Correale, P.; Rotundo, M. S.; DEL VECCHIO, M. T.; Remondo, C.; Migali, C.; Ginanneschi, C.; Tsang, K. Y.; Licchetta, A.; Mannucci, S.; Loiacono, L.; Tassone, P.; Francini, G.; Tagliaferri, P. | - | |
| Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients | 1-gen-2010 | Correale, P.; Remondo, C.; Carbone, S. F.; Ricci, V.; Migali, C.; Martellucci, I.; Licchetta, A.; Addeo, R.; Volterrani, L.; Gotti, G.; Rotundo, M. S.; Tassone, P.; Sperlongano, P.; Abbruzzese, A.; Caraglia, M.; Tagliaferri, P.; Francini, G. | - | |
| Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin | 1-gen-2010 | Petrioli, R.; Bargagli, G.; Lazzi, Stefano; Pascucci, A.; Francini, E.; Bellan, Cristiana; Conca, R.; Martellucci, I.; Fiaschi, A. I.; Lorenzi, B.; Francini, Guido; Multidisciplinary Oncology Group in Gastrointestinal, Tumors; Civitelli, Serenella | - | |
| Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate | 1-gen-2010 | Licchetta, A; Correale, P; Migali, C; Remondo, C; Francini, E; Pascucci, A; Magliocca, A; Guarnieri, Alfredo; Savelli, Vinno; Piccolomini, Alessandro; Carli, ANTON FERDINANDO; Francini, Guido | - | |
| Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractionated cisplatimum, oral etoposide, and bevacizumab | 1-gen-2009 | C., Remondo; C., Migali; I., Martellucci; F., Carbone; V., Ricci; R., Addeo; S., Del Prete; F., Fulfaro; Francini, Guido; P., Correale | - | |
| Association of immune-regulatory (FoxP3+)-T-cell tumor infiltration status with benefit from chemoimmunotherapy with gemcitabine, oxaliplatin, 5-FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients | 1-gen-2009 | Correale, P.; Tagliaferri, P.; Del Vecchio, M. T.; Remondo, C.; Migali, C.; Tsang, Ky.; Rotundo, M. S.; Fulfaro, F.; Tassone, P.; Francini, G. | - | |
| Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. | 1-gen-2009 | Correale, P; Miano, S. T; Remondo, C; Migali, C; Rotundo, M. S; Macrì, P; Tagliaferri, P; Tassone, P; Caraglia, M; Gotti, G; Francini, G. | - | |
| Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. | 1-gen-2009 | Sargent, D; Sobrero, A; Grothey, A; O'Connell, Mj; Buyse, M; Andre, T; Zheng, Y; Green, E; Labianca, R; O'Callaghan, C; Seitz, Jf; Francini, Guido; Haller, D; Yothers, G; Goldberg, R; DE GRAMONT, A. | - | |
| Immune-regulatory (FoxP3+)-T-cell tumor infiltration status is predictive of benefit from chemo-immunotherapy with gemcitabine, oxaliplatin, 5FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients | 1-gen-2009 | Remondo, C; Tagliaferri, P; Rotundo, M S; Tassone, P; Del Vecchio, M T; Migali, C; Francini, G; Correale, P | - | |
| Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractioned cisplatinum, oral etoposide and bevacizumab: phase IB/II study | 1-gen-2009 | Correale, P.; Remondo, C.; Migali, C.; Licchetta, A.; Martellucci, I.; Carbone, S. F.; Ricci, V.; Addeo, R.; Del Prete, S.; Francini, Guido | - | |
| Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. | 1-gen-2008 | Correale, P; DEL VECCHIO, MARIA TERESA; LA PLACA, M; Montagnani, F; DI GENOVA, G; Savellini, Gg; Terrosi, C; Mannucci, S; Giorgi, G; Francini, G.; Cusi, Mg | - | |
| Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. | 1-gen-2008 | Petrioli, R; Pascucci, A; Francini, E; Marsili, S; Sciandivasci, A; Tassi, R; Civitelli, Serenella; Tanzini, G; Lorenzi, Marco; Francini, Guido | - | |
| Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen | 1-gen-2008 | Correale, P.; Fioravanti, A.; Bertoldi, I.; Montagnani, F.; Miracco, C.; Francini, G. | - | |
| Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors | 1-gen-2008 | Petrioli, R.; Pascucci, A.; Francini, E.; Marsili, S.; Fiaschi, A. I.; Civitelli, S.; Tanzini, G.; Battistelli, S.; Lorenzi, M.; Roviello, F.; Francini, G. | - | |
| Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine. | 1-gen-2008 | Correale, P; DEL VECCHIO, MARIA TERESA; Renieri, Tommaso; DI GENOVA, Giuseppa; LA PLACA, M; Remondo, Cinzia; Savellini, Gg; Terrosi, C; Zurbriggen, R; Amacker, M; Francini, Guido; Cusi, MARIA GRAZIA | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile